Phase I/II Trial and Pharmacokinetic Study of Cixutumumab in Pediatric Patients With Refractory Solid Tumors and Ewing Sarcoma: A Report From the Children's Oncology Group

PURPOSE: A phase I/II study of cixutumumab (IMC-A12) in children with refractory solid tumors was conducted. This study was designed to assess the toxicities, pharmacokinetics, and pharmacodynamics of cixutumumab in children to determine a recommended phase II dose and to assess antitumor activity i...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Malempati, Suman, Weigel, Brenda, Ingle, Ashish M., Ahern, Charlotte H., Carroll, Julie M., Roberts, Charles T., Reid, Joel M., Schmechel, Stephen, Voss, Stephan D., Cho, Steven Y., Chen, Helen X., Krailo, Mark D., Adamson, Peter C., Blaney, Susan M.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2012
Matèries:
Original Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3269952/
https://ncbi.nlm.nih.gov/pubmed/22184397
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.37.4355
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars